166 related articles for article (PubMed ID: 35271729)
1. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
[TBL] [Abstract][Full Text] [Related]
2. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
4. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
6. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Waters MD; Warren S; Hughes C; Lewis P; Zhang F
Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
[TBL] [Abstract][Full Text] [Related]
7. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
8. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
9. A Nanopore Based Molnupiravir Sensor.
Jia W; Hu C; Wang Y; Zhang P; Chen HY; Huang S
ACS Sens; 2022 May; 7(5):1564-1571. PubMed ID: 35427117
[TBL] [Abstract][Full Text] [Related]
10. Two short approaches to the COVID-19 drug β-D-
Persaud KE; Sahu RR; Neary MC; Kapdi AR; Lakshman MK
Org Biomol Chem; 2024 Jan; 22(4):735-740. PubMed ID: 38168802
[TBL] [Abstract][Full Text] [Related]
11. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
Menéndez-Arias L
J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
[TBL] [Abstract][Full Text] [Related]
12. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva.
Amara A; Penchala SD; Else L; Hale C; FitzGerald R; Walker L; Lyons R; Fletcher T; Khoo S
J Pharm Biomed Anal; 2021 Nov; 206():114356. PubMed ID: 34509661
[TBL] [Abstract][Full Text] [Related]
13. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
Wallace KB; Bjork JA
Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
[TBL] [Abstract][Full Text] [Related]
14. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
[TBL] [Abstract][Full Text] [Related]
17. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.
Reçber T; Timur SS; Erdoğan Kablan S; Yalçın F; Karabulut TC; Neslihan Gürsoy R; Eroğlu H; Kır S; Nemutlu E
J Pharm Biomed Anal; 2022 May; 214():114693. PubMed ID: 35276385
[TBL] [Abstract][Full Text] [Related]
18. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
19. Molnupiravir: First Approval.
Syed YY
Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]